Want to see IN:AARTIDRUGS full AI Analyst Report?
AARTIDRUGS Stock Chart & Stats
₹404.80
-₹2.25(-0.50%)
At close: 4:00 PM EST
₹404.80
-₹2.25(-0.50%)
Day’s Range― - ―
52-Week Range₹318.60 - ₹534.15
Previous CloseN/A
Volume68.36K
Average Volume (3M)12.11K
Market Cap
₹39.40B
Enterprise Value₹34.83K
Total Cash (Recent Filing)₹242.80M
Total Debt (Recent Filing)₹5.77B
Price to Earnings (P/E)20.8
Beta0.90
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)21.35
Shares Outstanding91,270,000
10 Day Avg. Volume10,217
30 Day Avg. Volume12,113
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)1.88
Price to Sales (P/S)1.14
P/FCF Ratio59.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)22.4
Revenue Forecast (FY)₹28.70B
Bulls Say, Bears Say
Bulls Say
Improving Balance SheetLower leverage and a growing equity base improve financial flexibility and reduce balance-sheet risk. This should help Aarti Drugs fund operations and selected investments while remaining better positioned to withstand cyclical pricing or input-cost pressure.
Diversified B2B Product PortfolioExposure to APIs, intermediates, and specialty chemicals across pharmaceutical and industrial customers provides multiple demand channels. This diversification can reduce dependence on one product category and support longer-term resilience in a cyclical manufacturing environment.
Positive Operating Cash FlowPositive operating cash flow indicates that the core manufacturing business is generating cash from operations. While conversion into free cash flow remains imperfect, recurring operating cash generation provides an important foundation for working capital, debt service, and reinvestment.
Bears Say
Sustained Margin CompressionThe substantial decline in net margin signals weaker profitability than at the prior peak. If pricing remains pressured or costs stay elevated, reduced earnings resilience could limit internal funding capacity and make future growth less profitable.
Limited Revenue MomentumA largely stagnant revenue base suggests that volume growth, product mix, or customer expansion has not yet created a durable acceleration. Without stronger demand or higher-value product contribution, operating leverage and the ability to expand earnings may remain constrained.
Weak Free Cash Flow ConversionVolatile free cash flow and low conversion from net income indicate working-capital demands or continuing investment needs. This reduces the cash available for expansion, dividends, or debt reduction and makes reported earnings less dependable as a measure of financial flexibility.
Aarti Drugs Limited News
AARTIDRUGS FAQ
What was Aarti Drugs Limited’s price range in the past 12 months?
Aarti Drugs Limited lowest stock price was ₹318.60 and its highest was ₹534.15 in the past 12 months.
What is Aarti Drugs Limited’s market cap?
Aarti Drugs Limited’s market cap is ₹39.40B.
When is Aarti Drugs Limited’s upcoming earnings report date?
Aarti Drugs Limited’s upcoming earnings report date is Oct 22, 2026 which is in 45 days.
How were Aarti Drugs Limited’s earnings last quarter?
Aarti Drugs Limited released its earnings results on Jul 31, 2026. The company reported ₹5.497 earnings per share for the quarter, beating the consensus estimate of ₹5.4 by ₹0.097.
Is Aarti Drugs Limited overvalued?
According to Wall Street analysts Aarti Drugs Limited’s price is currently Overvalued.
Does Aarti Drugs Limited pay dividends?
Aarti Drugs Limited pays a Annually dividend of ₹2 which represents an annual dividend yield of 0.46%. See more information on Aarti Drugs Limited dividends here
What is Aarti Drugs Limited’s EPS estimate?
Aarti Drugs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aarti Drugs Limited have?
Aarti Drugs Limited has 91,270,000 shares outstanding.
What happened to Aarti Drugs Limited’s price movement after its last earnings report?
Aarti Drugs Limited reported an EPS of ₹5.497 in its last earnings report, beating expectations of ₹5.4. Following the earnings report the stock price went up 2.642%.
Which hedge fund is a major shareholder of Aarti Drugs Limited?
Currently, no hedge funds are holding shares in IN:AARTIDRUGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aarti Drugs Limited
Operating both within India and globally, Aarti Drugs Limited, along with its affiliated companies, specializes in the pharmaceutical sector. Its product portfolio encompasses a wide range of active pharmaceutical ingredients (APIs) across numerous therapeutic areas, such as anti-inflammatory, cardiovascular protection, antidiarrheal, antifungal, anti-arthritis/osteoporosis, antibiotic, antidiabetic, Alzheimer's disease management, sedative, vitamin, and alcoholism treatment. Additionally, it supplies pharmaceutical intermediate compounds, including tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. Furthermore, the company manufactures and distributes various specialty chemicals. These include a comprehensive list of compounds such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, sodium benzene sulfinate, para toluene sulphonyl hydrazide, benzene sulphonic acid and its sodium salt, benzyl nicotinate, bisphenol C, bisphenol C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. Aarti Drugs also maintains a robust development pipeline, featuring products such as Acamprosate, intended for treating alcoholism; Dabigatran, an anticoagulant; Sevelamer, for managing hyperphosphatemia; Colesevelam, aimed at lowering cholesterol; Dronedarone and Olmesartan, both for cardiovascular disease treatment; Valsartan, which acts as a cardioprotectant; and Sitagliptin, an antidiabetic agent. Moreover, the firm provides contract manufacturing solutions. Established in 1984, the company's main operations are based in Mumbai, India.
Technical Analysis
Granules India Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Neuland Laboratories Ltd.
―
Solara Active Pharma Sciences Ltd.
―